QSAR in Development of Antidepressants

More documents

Recommendations

Info

Stagnant progression • Serious Drawback to SSRIs – delay of therapeutic benefit • two to six weeks for response – low rate of response – low rate of remission • Delayed response due to 5-HT 1a inhibition • 5-HT 1A desensitization normal firing – therapeutic effect
Serotonin effect Phil Skolnick, P. P., Aaron Janowsky, Bernard Beer, Arnold S. Lippa. European journal of pharmacology. 2003, 461, 99-104.
Page 1 and 2: The Next Generation of Antidepressa
Page 3 and 4: Depression as a Disease • 1 out 5
Page 5: Serotonin Hypothesis • serotonerg
Page 9 and 10: Project Aim • explore a faster ac
Page 11 and 12: QSAR Design • Create training set
Page 13 and 14: Why use GFA • builds multiple mod
Page 15 and 16: • r 2 =.87 QSAR results • valid
Page 17 and 18: Strategy Nh 2 fluoxetine F Cl O H N
Page 19 and 20: Synthetic scheme S antidepressants
Page 21 and 22: Synthetic scheme
Page 23: References • Phil Skolnick, P. P.

QSAR in Development of Antidepressants

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?